Table of Contents
Installation of Mizotac tablets
Each tablet contains: Active ingredient: Misoprostol 200 micrograms Inactive ingredients: croscarmellose sodion, Aerosil 200, microcrystalline cellulose.
Pharmaceutical form of Mesotac rivet
Mizotac tablets
Pharmacological effect of Mesotac tablets
Mesotac Tablets is an analogue of I ‘8luraUy that occurs for prostaglandin E1 that promotes the treatment of peptic ulcers and symptom relief. Misobc protects the gastric mucosa duodenum by inhibiting the basal, catalytic and nocturnal acid S8CI’1 which reduces the yOIume of gastric secretions, the haemolytic activity of gastric fluid, and the increased mucus secretion greatly affects pregnancy causing miscarriage and termination of pregnancy
Pharmacokinetics Mizotac tablets
Mizotac tablets is rapidly absorbed through oral administration, with peak plasma Ievets of active rneta (rrisoprostoI acid) occurring after about 30 million tons plasma elimination half-life of misoprosto I8I min. There is no documentation of misoprostoy acid in plasma oc: om after repeated doses of 400 mcg: roor daily
Uses of Mizotac tablets
Mesotac Tablets is used to treat duodenal ulcers and stomach ulcers including those caused by the anti-inflammatory drug (NSAlD) in high-risk arthritis patients, while continuing treatment with NSAIDs. Misotac can be used to prevent ulcers caused by NSAIDs. It is used for medical abortion and termination of pregnancy.
Dosage and abuse Mesotac tablets
For use under medical supervision for adults: healing of duodenal ulcers, stomach: ulcers and NSAIDs induced 1: 800 mcg daily in four divided doses with breakfast and the first or each main meal and at bedtime. Treatment should be given initially for at least 4 weeks even if symptoms are relieved
Most patients recover within 4 years, but treatment may continue for up to 8 weeks. If the ulcer relapses, more treatment courses can be given. Prevention of NSAlD-induced peptic ulcers: 200 mcg twice daily. Three lemons daily of four types treatment may be required and drDo.age 6houId is individual according to the clinical conditions of each patient
Older adults and Mesotac
The usual dose can be used. RenaJ ~ ‘AvUabIe n evidence: indicates that no dose adjustment is necessary in hepatic insufficiency patienb inpainnenl. The mesotac is metabolized by the fatty acid oxidation systems present in thmugI body organs. Therefore it is unlikely that metabolism and plasma levels would be significantly affected in impaired patients; significantly in impaired patients.
children
The use of Mesotac in children in treating peptic ulcers or peptic ulcer disease with NSAIDs has not yet been evaluated.
Mizotac contraindications
Mesotac is contraindicated in patients with known prostaglandin allergy.
Side effects of Mesotac tablets
Gastrointestinal / GI tract infection: Diarrhea has been reported and is occasionally severe and prolonged and may require drug withdrawal. This can be minimized by using single doses not exceeding 200 mcg with food and by aVOiding the use of antacids containing mostly magnesium when an antacid is required.
. Misoprostol treatment may be followed by abdominal pain, with or without indigestion or udder disease. Other gastrointestinal adverse effects reported dyspepsia, gonorrhea, nausea and vomiting. Female reproductive system: Menstruation, vaginal bleeding and intermenstrual bleeding have been reported in postmenopausal women. Other side effects: Skin rash has been reported. Dizziness is rarely treated. The range of side effects associated with Mlsotac is similar when NSAIDs are administered concurrently. A number of side effects 01 have been reported in Denical studies or in the literature following the use of misoprostol 01 for unapproved indications and these include: abnormal uterine contractions, uterine bleeding , retained placenta, Amniotic nuclear embolism, incomplete miscarriage and premature labor.
Pregnancy and breast-feeding:
Mesotac Tablets is contraindicated in pregnant women and women planning a pregnancy because it reduces uterine tension and joint contractions in pregnancy whid1
may cause pregnancy abortion
References
- Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J (2002). “Prevention of NSAID-induced gastroduodenal ulcers”. The Cochrane Database of Systematic Reviews (4): CD002296. doi:10.1002/14651858.CD002296. PMID 12519573. S2CID 1052260.
- ^ Jump up to:a b c d e f g “Misoprostol”. The American Society of Health-System Pharmacists. Archived from the original on 21 February 2015. Retrieved 20 February 2015.
- ^ Jump up to:a b Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A (November 2011). “Medical methods for first trimester abortion”. The Cochrane Database of Systematic Reviews (11): CD002855. doi:10.1002/14651858.CD002855.pub4. PMC 7144729. PMID 22071804. S2CID 205167182.
- ^ Bryant AG, Regan E, Stuart G (January 2014). “An overview of medical abortion for clinical practice”. Obstetrical & Gynecological Survey. 69 (1): 39–45. doi:10.1097/OGX.0000000000000017. PMID 25102250. S2CID 28486936.
- ^ Raymond EG, Harrison MS, Weaver MA (January 2019). “Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review”. Obstetrics and Gynecology. 133 (1): 137–147. doi:10.1097/AOG.0000000000003017. PMC 6309472. PMID 30531568.
- ^